Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Biol Chem
2010 Oct 29;28544:33898-905. doi: 10.1074/jbc.M110.159897.
Show Gene links
Show Anatomy links
Overlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1.
Madeja M
,
Steffen W
,
Mesic I
,
Garic B
,
Zhorov BS
.
???displayArticle.abstract??? Kv2.1 channels, which are expressed in brain, heart, pancreas, and other organs and tissues, are important targets for drug design. Flecainide and propafenone are known to block Kv2.1 channels more potently than other Kv channels. Here, we sought to explore structural determinants of this selectivity. We demonstrated that flecainide reduced the K(+) currents through Kv2.1 channels expressed in Xenopus laevis oocytes in a voltage- and time-dependent manner. By systematically exchanging various segments of Kv2.1 with those from Kv1.2, we determined flecainide-sensing residues in the P-helix and inner helix S6. These residues are not exposed to the inner pore, a conventional binding region of open channel blockers. The flecainide-sensing residues also contribute to propafenone binding, suggesting overlapping receptors for the drugs. Indeed, propafenone and flecainide compete for binding in Kv2.1. We further used Monte Carlo-energy minimizations to map the receptors of the drugs. Flecainide docking in the Kv1.2-based homology model of Kv2.1 predicts the ligand ammonium group in the central cavity and the benzamide moiety in a niche between S6 and the P-helix. Propafenone also binds in the niche. Its carbonyl group accepts an H-bond from the P-helix, the amino group donates an H-bond to the P-loop turn, whereas the propyl group protrudes in the pore and blocks the access to the selectivity filter. Thus, besides the binding region in the central cavity, certain K(+) channel ligands can expand in the subunit interface whose residues are less conserved between K(+) channels and hence may be targets for design of highly desirable subtype-specific K(+) channel drugs.
Andér,
Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model.
2008, Pubmed
Andér,
Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model.
2008,
Pubmed
Archer,
Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells.
2004,
Pubmed
Bruhova,
Monte Carlo-energy minimization of correolide in the Kv1.3 channel: possible role of potassium ion in ligand-receptor interactions.
2007,
Pubmed
Choi,
The internal quaternary ammonium receptor site of Shaker potassium channels.
1993,
Pubmed
,
Xenbase
Chung,
Biochemical characterization of the native Kv2.1 potassium channel.
2005,
Pubmed
Decher,
Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
2004,
Pubmed
,
Xenbase
Doyle,
The structure of the potassium channel: molecular basis of K+ conduction and selectivity.
1998,
Pubmed
Dreker,
Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state.
2005,
Pubmed
Faraldo-Gómez,
Mechanism of intracellular block of the KcsA K+ channel by tetrabutylammonium: insights from X-ray crystallography, electrophysiology and replica-exchange molecular dynamics simulations.
2007,
Pubmed
Garden,
Docking flexible ligands in proteins with a solvent exposure- and distance-dependent dielectric function.
2010,
Pubmed
Hockerman,
Molecular determinants of drug binding and action on L-type calcium channels.
1997,
Pubmed
Huang,
Early down-regulation of K+ channel genes and currents in the postinfarction heart.
2000,
Pubmed
Jacobson,
Kv2.1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion.
2007,
Pubmed
Kaczorowski,
Pharmacology of voltage-gated and calcium-activated potassium channels.
1999,
Pubmed
Lazaridis,
Effective energy function for proteins in solution.
1999,
Pubmed
Lenaeus,
Structural basis of TEA blockade in a model potassium channel.
2005,
Pubmed
Li,
Monte Carlo-minimization approach to the multiple-minima problem in protein folding.
1987,
Pubmed
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Long,
Crystal structure of a mammalian voltage-dependent Shaker family K+ channel.
2005,
Pubmed
MacDonald,
Inhibition of Kv2.1 voltage-dependent K+ channels in pancreatic beta-cells enhances glucose-dependent insulin secretion.
2002,
Pubmed
Madeja,
Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1.
2003,
Pubmed
,
Xenbase
Madeja,
A concentration-clamp system allowing two-electrode voltage-clamp investigations in oocytes of Xenopus laevis.
1991,
Pubmed
,
Xenbase
Misonou,
Regulation of ion channel localization and phosphorylation by neuronal activity.
2004,
Pubmed
Nishiyama,
Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle.
1998,
Pubmed
Patel,
Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes.
1997,
Pubmed
Qin,
Downregulation of K(+) channel genes expression in type I diabetic cardiomyopathy.
2001,
Pubmed
Roe,
Expression and function of pancreatic beta-cell delayed rectifier K+ channels. Role in stimulus-secretion coupling.
1996,
Pubmed
Rolf,
Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes.
2000,
Pubmed
,
Xenbase
Rossokhin,
Interaction of d-tubocurarine with potassium channels: molecular modeling and ligand binding.
2006,
Pubmed
Sanguinetti,
hERG potassium channels and cardiac arrhythmia.
2006,
Pubmed
Schmitz,
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
2005,
Pubmed
Schultz,
Heterogeneity of Kv2.1 mRNA expression and delayed rectifier current in single isolated myocytes from rat left ventricle.
2001,
Pubmed
Snyders,
Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel.
1992,
Pubmed
Tikhonov,
Sodium channels: ionic model of slow inactivation and state-dependent drug binding.
2007,
Pubmed
Tikhonov,
Molecular modeling of benzothiazepine binding in the L-type calcium channel.
2008,
Pubmed
Valenzuela,
Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes.
1995,
Pubmed
Valenzuela,
Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers.
1995,
Pubmed
Wareing,
Expression and function of potassium channels in the human placental vasculature.
2006,
Pubmed
Wible,
Stable expression and characterization of the human brain potassium channel Kv2.1: blockade by antipsychotic agents.
1997,
Pubmed
,
Xenbase
Wulff,
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.
2008,
Pubmed
Xu,
Attenuation of the slow component of delayed rectification, action potential prolongation, and triggered activity in mice expressing a dominant-negative Kv2 alpha subunit.
1999,
Pubmed
YALE,
The trifluoromethyl group in medicinal chemistry.
1959,
Pubmed
Zhorov,
Potassium, sodium, calcium and glutamate-gated channels: pore architecture and ligand action.
2004,
Pubmed
Zhou,
Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors.
2001,
Pubmed
,
Xenbase